For decades, the biotech company Genentech has carved out a reputation in the industry as a scientist’s paradise, a place ...

The recent decision to merge Genentech’s two cancer departments was made for “scientific reasons,” executives explained to ...

AstraZeneca's Imfinzi was used before and after surgery in a clinical trial of patients with muscle-invasive bladder cancer — ...

It’s unclear if the layoffs are connected to Genentech’s closure of its cancer immunology research department, which Fierce Biotech reported earlier this month would include some layoffs.

Earlier this month, Genentech told Fierce Biotech it would close its cancer immunology research department located in South San Francisco, with the specific research functions destined to be ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

Last month, Roche Holding AG, Genentech’s parent company, announced the sale of the drugmaker’s manufacturing facility in ...

Biotech giant Genentech's latest earnings report signaled blue skies for the company, with the exception of one ominous storm cloud: Avastin. Despite posting a nearly 80% jump in profits during ...

Roche’s Genentech unit has bought California biotech Jecure Therapeutics, which is researching drugs that could be used in inflammatory diseases including the fatty liver disease NASH.

This began a revolution in molecule production that culminated in the founding of Genentech, the first publicly-owned biotech company, in 1976. Like many biotech startups today, Genentech started ...

For decades, the biotech company Genentech has carved out a reputation in the industry as a scientist’s paradise, a place where researchers have developed new therapies in-house and published ...